AOD9604 5mg

AOD9604 5mg — Modified Human Growth Hormone Fragment (176–191)

AOD9604 (historically designated “Anti-Obesity Drug 9604”) is a synthetic 16-amino-acid peptide based on residues 176–191 of the C-terminal end of human growth hormone, with an additional N-terminal tyrosine. Originally developed by Metabolic Pharmaceuticals (Australia) in the early 2000s, it has been investigated extensively in metabolic and lipolysis research as a fragment that retains hGH’s fat-mobilising activity without its insulin-like or growth-promoting effects.

Supplied as lyophilised solid at ≥99% purity (HPLC verified), UK-dispatched by OL Research. For laboratory and in-vitro research use only.

Key Research Areas

• Lipolysis & fat-cell metabolism — Studied in adipocyte models for stimulation of lipolytic activity and inhibition of lipogenesis; investigated for selective fat-mobilising effects independent of GH receptor signalling
• Cartilage & joint research — Examined in chondrocyte models and osteoarthritis frameworks for anabolic effects on cartilage matrix synthesis
• Metabolic profile — Investigated for absence of the hyperglycaemic and IGF-1-elevating effects associated with full-length hGH, making it a useful tool compound for isolating GH’s metabolic effects
• Body composition models — Studied in rodent obesity models for changes in fat mass, lean mass, and energy expenditure
• Clinical research history — Progressed to early-phase human trials in Australia (2000s) for obesity and osteoarthritis indications; subsequently discontinued for therapeutic development

Product Specifications

About the Compound

AOD9604 was developed by Professor Frank Ng and colleagues at Monash University and licensed to Metabolic Pharmaceuticals Limited. It was designed to isolate the fat-metabolising activity localised to the C-terminal region of human growth hormone, while removing the receptor binding responsible for GH’s growth-promoting and insulin-antagonistic effects.

The peptide proceeded through Phase IIb clinical trials for obesity, where it demonstrated favourable safety but failed to meet weight-loss endpoints at the doses tested. Subsequent research has investigated AOD9604 in cartilage repair and osteoarthritis contexts. It is now widely used in research settings as a tool compound for studying GH-derived fragments and selective lipolytic signalling.

Unlike full-length hGH, AOD9604 does not bind the growth hormone receptor and does not elevate IGF-1 or interfere with glucose homeostasis in published research models — a distinction that has made it a valuable comparator compound in metabolic studies.

Frequently Asked Questions

What is AOD9604 derived from?
It is a synthetic peptide modelled on residues 176–191 of the C-terminal end of human growth hormone, modified by adding a tyrosine residue to the N-terminus to improve stability. It is fully synthesised in the laboratory, not extracted.

How does AOD9604 differ from full-length hGH?
AOD9604 retains GH’s lipolytic (fat-mobilising) activity but lacks its growth-promoting and insulin-antagonistic effects in published research models. It does not bind the GH receptor or elevate IGF-1 levels.

What purity is supplied?
≥99%, HPLC verified. Certificate of analysis available on request.

Is this for human use?
No. Supplied strictly for in-vitro and laboratory research. Not a medicine, supplement, or food product.

Related Research Compounds

• Tesamorelin 10mg — GHRH analogue; lipolysis and visceral fat research
• CJC-1295 No DAC 10mg — GHRH analogue; growth hormone secretagogue research
• Ipamorelin 10mg — Selective GH secretagogue; receptor pharmacology research
• MOTS-C 10mg — Mitochondrial-derived peptide; metabolic regulation research

Key Research References

• Ng FM et al. (2000) — Metabolic studies of a synthetic lipolytic domain (AOD9401) of human growth hormone. Hormone Research
• Heffernan M et al. (2001) — The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice. Endocrinology
• Kwon DR, Park GY (2015) — Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science

⚠️ For laboratory and in-vitro research use only. Not for human consumption, veterinary use, or clinical application. OL Research products are supplied in compliance with UK regulations governing research compounds.